Assessment of HER2 status in breast cancer
- 1 January 2000
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 36 (2), 170-176
- https://doi.org/10.1016/s0959-8049(99)00264-6
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Lack of correlation betweenc-erbB-2 overexpression and the effect of dose-intensification of adjuvant chemotherapy in high-risk breast cancer patientsEuropean Journal Of Cancer, 1998
- P46 15 year update of the naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and Tamoxifen efficacyEuropean Journal Of Cancer, 1998
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Quantitative radioimmunohistochemical measurements of p185(erbB-2) in frozen tissue sections.Journal of Histochemistry & Cytochemistry, 1996
- c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancerEuropean Journal Of Cancer, 1995
- Analysis of cerbB2 expression using a panel of 6 commercially available antibodiesPathology, 1994
- Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivityEuropean Journal Of Cancer, 1993
- Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?European Journal Of Cancer, 1992
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987